Navigation Links
IMDx Obtains CE-Marking for an Automated Molecular Test for Detection and Differentiation of Herpes Simplex Viruses 1 and 2
Date:7/19/2012

CAMBRIDGE, Mass., July 19, 2012 /PRNewswire/ -- IntelligentMDx (IMDx) announced today that it has obtained CE-marking for its fourth automated, high-throughput molecular test designed and developed for the Abbott m2000 System. The IMDx HSV-1/2 for Abbott m2000 detects Herpes Simplex Virus (HSV) viral DNA and differentiates HSV-1 and HSV-2 in male and female genital or oral lesions and cerebral spinal fluid (CSF).

(Logo:  http://photos.prnewswire.com/prnh/20120306/NE63745LOGO )

HSV is the most common cause of genital and oral lesions, but can also invade other human tissue, occasionally causing keratitis, encephalitis, meningitis, and neonatal sepsis.  Globally, an estimated 4.0 billion people are currently infected with HSV and the worldwide incidence of HSV-1 infection is considered the second largest, surpassed only by incidences of the common cold.(1) 

"We are proud to play a role in easing the global burden of herpes virus infections through rapid and precise diagnostics." Says Dr. Alice Jacobs, MD, Chairman & CEO of IntelligentMDx.  "Automated, high-throughput molecular diagnostics are becoming the method of choice for fast and reliable diagnosis of infections. The robust performance and automated nature of the IMDx HSV-1/2 for Abbott m2000 assay can aid in the diagnosis of patients and support faster treatment decisions."

The IMDx HSV-1/2 for Abbott m2000 assay offers a fully automated method for accurate testing of up to 94 patient samples simultaneously in less than 6 hours. Minimal hands-on time is required as results are obtained using a direct swab taken from a symptomatic male or female patient. When compared against clinical samples classified for HSV-1 and HSV-2 using culture and a molecular reference method, the IMDx HSV-1/2 for Abbott m2000 demonstrated 100.0% sensitivity and 97.2% specificity for HSV-1 and 100.0% sensitivity and 98.8% specificity for HSV-2.

The IMDx HSV-1/2 for Abbott m2000 assay is part of a series of infectious disease diagnostic tests designed by IMDx for use on the Abbott m2000 system. The IMDx CE-marked test menu for use on the Abbott m2000 system includes real-time PCR assays for the detection of Group B Streptococcus, vancomycin resistant Enterococci (vanA/ vanB) and toxigenic C. difficile.

This assay is CE-marked and not available for sale in the U.S. or Canada.

(1) Global Industry Analysts, Inc. 2011

About IMDx
Based in Cambridge, MA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs.


'/>"/>
SOURCE IntelligentMDx
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
2. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
3. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
4. Sifting liquid at the molecular level
5. Neogen launches the fastest molecular pathogen test
6. Strange cousins: Molecular alternatives to DNA, RNA offer new insight into lifes origins
7. GenScript Rush Gene Synthesis - Driving Molecular Biology Research Faster
8. Molecular graphene heralds new era of designer electrons
9. Molecular Detection Inc. Completes $1.5 Million Financing to Advance New Tests for Sepsis and GI Disorders
10. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
11. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become the ... corporate cooking challenges for companies around the world, such as Illumina, HP and Qualcomm, and ... reason for its increasing popularity is due to its new team building format, a way ...
(Date:3/23/2017)... MILFORD, Mass. , March 23, 2017 ... leading partner to global in vitro diagnostics ... launch of the industry,s first multiplexed ... inherited disease testing by next-generation sequencing ... materials were developed with input from industry ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen ... the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff ... of Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, ...
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
Breaking Biology Technology:
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):